Refine Your Approach to Regulatory Compliance
We spoke with regulatory partners to uncover what really matters when it comes to getting your compliance right first time. The answer was unanimous; compliance isn’t a box to tick at the end of development. It is a foundation for commercial success, and the decisions you make in the early days will determine whether your product reaches the market effectively or gets trapped in costly delays and remediation.
For CEOs stepping into this complex landscape, the challenge is less about memorising regulations and more about setting the right strategy. Here’s what the experts believe every MedTech leader should know.
________________________________________
Build the Right Foundations from Day One
The most successful leaders don’t wait until a prototype is finished before thinking about compliance. They ask the hard questions up front: what problem are we really solving? Who will use and buy the product, and in which markets? And perhaps most importantly, how will we gather the clinical evidence needed to prove benefit to regulators, investors, and payers?
This isn’t just an academic exercise. These questions frame your regulatory roadmap; from classification and applicable standards to the requirements of a quality management system. When done early, it means compliance grows alongside your product design, commercial strategy, and funding plan rather than holding them back.
________________________________________
Avoid the Pitfalls that Sink Startups
One of the most common mistakes is underestimating just how expensive and time-consuming regulatory approval really is. Quality management systems, external testing, clinical investigations, and conformity assessments all carry significant costs. Miss them in your financial plan, and you risk running out of funding mid-development. The usual response, rushing evidence or cutting corners, only leads to remediation, more expense, and long delays.
Another trap is giving in to your confirmation bias and relying on poor advice because it is what you want to hear. Well-meaning but inexperienced advisors can leave you on the wrong path for months. Worse still, some startups base critical regulatory decisions on generic online information. It is no exaggeration to say that the right guidance at the right moment can save you years of effort.
________________________________________
Strategy Means Integrating Regulatory and Commercial Plans
Too often, CEOs see compliance and commercialisation as separate challenges. In reality, they are inseparable. Your ability to sell in a given market is dictated by your ability to meet its regulatory requirements.
That is why defining your intended use and commercial claims early matters so much. A clear definition of what your product will do, and what you will claim about it, sets the tone for the regulatory pathway. Sometimes narrowing the scope of your initial launch can open the door to faster approvals, quicker revenue, and a stronger foundation for later expansion.
________________________________________
Evidence Is Non-Negotiable
Clinical evidence is no longer a “nice to have”. Regulators, payers, and clinicians all expect robust data to demonstrate safety and benefit. The days of leaning heavily on equivalence are gone.
What this means in practice is that CEOs must treat clinical development as an integral part of the business plan. Cutting corners may look like progress in the short term, but it creates serious problems later. Without sufficient evidence, market access becomes almost impossible, and clinical adoption, the ultimate test of success, will simply not follow.
________________________________________
Quality Systems That Enable Innovation
Quality management systems can be either your biggest liability or your greatest enabler. Poorly designed systems often slow innovation, frustrate teams, and create compliance gaps that undermine trust with regulators and investors.
By contrast, a right-sized QMS, lean, proportionate, and resourced appropriately, becomes a growth asset. It allows faster decision-making, smoother audits, and better resilience as you scale. For software-based devices, choosing the right digital tools is particularly important. Attempting to manage design controls in spreadsheets quickly collapses under the weight of iteration. Integrated platforms that link requirements, risks, verification, and change management in one place are far more effective, provided they are proportionate to your company’s size and maturity.
________________________________________
Compliance as a Growth Strategy
The strongest message is that compliance is not a barrier; it is a benefit. When CEOs engage with the right expertise early, align regulatory and commercial priorities, and make realistic plans for costs and evidence, compliance becomes a competitive advantage. It speeds up market access, builds investor confidence, and fosters trust with clinicians and patients alike.
For MedTech leaders, the mindset shift is clear. Stop asking how to minimise the burden, and start asking how to maximise the advantage. Those who do will not only get compliance right the first time, they will build companies ready to scale and succeed.
________________________________________
About the Contributors
Health Tech Enterprise extends its thanks to our valued regulatory partners for their input into this article.
• Jacob Skinner, Global Regulatory Services (GRS)
• Matthew Burton, David Hawkins, SOTAS
• Jonathan Ripley, Ben Austin, IMED Consultancy
